PsychedelicNewsBreaks Archive - Page 46 of 68

FridayJun 25, 2021 10:22 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate in Fireside Chat at Grizzle Psychedelics Con

Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The fireside chat is slated to begin at 12:30 p.m. ET and will be webcast live at https://ibn.fm/Ec3zS with an archived version available after the event. To view the full press release, visit https://ibn.fm/XFm9j About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel…

ThursdayJun 24, 2021 1:48 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Medicinal Cannabis Space Through Strategic Agreement

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, together with Canada House Wellness Group (CSE: CHV), a fully integrated medical cannabis company, have entered into a medical supply agreement. Under the agreement, Canada House’s wholly owned subsidiary, Abba Medix Corp., will purchase Pure Extracts’ full line of concentrate products for sale to its established medical patient base. “This agreement marks our entry into the medical cannabis space, which will make a significant revenue contribution starting in Q4 and ramping-up in 2022,” said Pure…

ThursdayJun 24, 2021 10:15 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the company and its drug development pipeline, with his presentation scheduled to begin at 11:50 a.m. ET. In addition, McKee will contribute to a panel discussion on the future of research and development activities for psychedelic drug compounds. To view the full press release, visit https://ibn.fm/ehNS8…

ThursdayJun 24, 2021 10:03 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA, Laughren oversaw the review of all psychiatric drug-development activities conducted under Investigational New Drug (“IND”) as well as the review of all New Drug Applications (“NDAs”) and supplements for new psychiatric drug claims. He served for 29 years and received numerous awards for his regulatory accomplishments. "As we study psychedelic medicines, the regulatory pathway ahead is still coming into…

WednesdayJun 23, 2021 1:38 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Participation at Life Sciences Investor Forum

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale will provide an overview of the company, including key information targeting the forum audience. Drysdale’s presentation is scheduled for 9 a.m. ET; an archived version of the presentation will be available following the event. The Life Sciences Investor Forum is designed to be a live, interactive online event where attendees are invited to ask participating companies questions in real time. To view the full presentation,…

TuesdayJun 22, 2021 1:18 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for Parkinson’s Disease was completed in March 2021. Due to the favorable outcome of the study, the Rotigotine development program will be advanced to include a pivotal human trial.” The article, which documented XPhyto’s advancements so…

TuesdayJun 22, 2021 10:56 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes 51st Pre-Clinical Psychedelic Molecule Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational New Drug (“IND”) process. The 51st study was an in-vitro and in-vivo evaluation of Cybin’s growing number of psychedelic compounds being designed and evaluated for potential therapeutic applications to treat a number of mental health situations. The announcement noted that, to date, the Cybin research and development team has evaluated more than 50 novel compounds for pharmacokinetic properties, metabolic stability, receptor binding and safety in order…

MondayJun 21, 2021 11:11 am

PsychedelicNewsBreaks – Psychedelic Capital: June 2021 to Feature Top Companies, Newest Opportunities, Deep Industry Insights

Microdose Psychedelic Insights, a cutting-edge media company focused on providing content, analysis and engaging events designed to drive the psychedelics industry to the forefront of modern medicine, will be hosting the upcoming Psychedelic Capital: June 2021. The conference is slated to take place in an entirely virtual format on June 30, 2021. The event will feature some of the top companies, latest IPOs, newest opportunities, and deepest industry insights within the sector. The Psychedelic Capital conference is part of an investor conference series diving deep into psychedelic medicine investment. An introductory talk delivered by Richard Skaife, Patrick Moher and Henri…

MondayJun 21, 2021 10:27 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at the Emerging Growth Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced that its CEO Doug Drysdale will be participating at the 2021 Emerging Growth Conference, which is scheduled for June 23, 2021. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at 2 p.m. ET. Interested individuals can register to view the Cybin executive’s presentation via the webcast. Following the conference, an archived version of the presentation will be available at www.EmergingGrowth.com. To view the presentation, visit https://ibn.fm/i4DMQ To view the full press release, visit…

ThursdayJun 17, 2021 10:52 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s achievements and future plans. XPhyto Therapeutics recently secured European approval and launched an effective 25-minute polymerase chain reaction (“PCR”) test for COVID-19 (“Covid-ID Lab”), with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company.…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks